UCB of Belgium posted net sales for the first half of 1994 of 25.2 billion Belgian francs ($775.43 million), up 7.5% on the previous year. Pretax profit was down 19.8% to just over 2 billion francs and net profit declined 29.5%. However, the company points out that ordinary pretax profits were ahead 21% at 1.3 billion francs. UCB said that the pharmaceutical sector had been favorably affected by the demand for its antihistamine Zyrtec (cetirizine), which is normally stronger in the spring.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze